MedTrace Logo

Active Surveillance for Low Risk Prostate Cancer

NCT04146077 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2021-07-22

No results posted yet for this study

Summary

An active surveillance protocol for patients diagnosed low-risk prostate cancer will be held. We plan to use PSA (prostate-specific antigen) testing, DRE (digital rectal examination), TRUS (transrectal ultrasound), MRI (magnetic resonance imaging) and follow-up biopsies to monitor patients and detect cancer progression in time.

Conditions

Sponsors & Collaborators

  • Moscow Regional Research and Clinical Institute (MONIKI)

    collaborator OTHER_GOV

  • Pirogov Russian National Research Medical University

    collaborator OTHER

  • I.M. Sechenov First Moscow State Medical University

    lead OTHER

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2024-10-31
Completion
2026-10-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04146077 on ClinicalTrials.gov